Overview
Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class. Fluvastatin is a racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin.
Indication
To be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart disease (CHD) to reduce the risk of requiring coronary revascularization procedures, for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with CHD, and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia.
Associated Conditions
- Atherosclerosis
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Mixed Dyslipidemias
- Primary Hypercholesterolemia
- Revascularization procedures
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2020/02/26 | Early Phase 1 | Withdrawn | |||
2019/07/23 | Phase 4 | Completed | |||
2018/04/27 | Phase 3 | Completed | |||
2018/04/27 | Phase 3 | Completed | |||
2018/01/08 | Not Applicable | Completed | |||
2017/06/16 | Phase 4 | Completed | |||
2015/08/07 | N/A | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | ||
2015/08/07 | N/A | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | ||
2014/04/15 | Phase 1 | Completed | |||
2013/11/25 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Carilion Materials Management | 68151-4471 | ORAL | 80 mg in 1 1 | 3/1/2012 | |
| Bryant Ranch Prepack | 63629-8812 | ORAL | 20 mg in 1 1 | 8/31/2020 | |
| Physicians Total Care, Inc. | 54868-4224 | ORAL | 40 mg in 1 1 | 3/23/2011 | |
| Teva Pharmaceuticals USA, Inc. | 0093-7446 | ORAL | 80 mg in 1 1 | 10/7/2022 | |
| Carilion Materials Management | 68151-1326 | ORAL | 20 mg in 1 1 | 1/25/2013 | |
| Mylan Pharmaceuticals Inc. | 0378-8021 | ORAL | 40 mg in 1 1 | 8/20/2020 | |
| Physicians Total Care, Inc. | 54868-4601 | ORAL | 80 mg in 1 1 | 3/23/2011 | |
| Physicians Total Care, Inc. | 54868-3329 | ORAL | 20 mg in 1 1 | 3/23/2011 | |
| Carilion Materials Management | 68151-1334 | ORAL | 40 mg in 1 1 | 1/25/2013 | |
| Novartis Pharmaceuticals Corporation | 0078-0354 | ORAL | 80 mg in 1 1 | 11/7/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| LESCOL XL fluvastatin 80mg tablet blister pack | 82743 | Medicine | A | 9/17/2002 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.